1. Introduction {#sec1}
===============

Infection with hepatitis B virus (HBV) remains a frequent etiology of cirrhosis and hepatocellular carcinoma with estimated 360 million individuals with chronic infection worldwide \[[@B1]\]. Although vaccination will ultimately reduce the disease burden due to HBV, antiviral therapy can favorably alter its natural history \[[@B2]\]. Goals of therapy include suppression of HBV replication to delay progression of liver disease reducing the risk of hepatic decompensation and hepatocellular carcinoma as well as infectivity to other individuals. Although standard interferon alpha was licensed for the treatment of chronic HBV infection over two decades ago more widespread therapy became feasible with the advent of well-tolerated oral antiviral nucleoside and nucleotide agents. However, shortly after the introduction of the first nucleoside analogue, lamivudine, treatment induced mutations in the viral genome were identified. These mutations resulted in reduced antiviral efficacy and diminished clinical benefit. Subsequently adefovir, a nucleotide analogue, efficacious in presence of lamivudine induced mutations was licensed, but its use was also associated with emergence of genomic antiviral resistance. Antiviral resistance has also been identified with more recently introduced nucleoside analogue, telbivudine, and entecavir but to date no clinically significant mutations have been recognized with tenofovir, a nucleotide analogue.

Society guidelines and treatment algorithms endorse close monitoring of subjects treated with oral antiviral therapies for development of viral mutants \[[@B3]--[@B5]\]. A resistance mutation is an amino acid change that decreases sensitivity to an antiviral drug. Mutations can be divided into primary and secondary mutations, the former an amino acid substitution that results in decreased susceptibility to an antiviral agent, whereas the latter is compensatory amino acid substitution(s) restoring the functional defect in the HBV polymerase activity associated with primary drug resistance; hence, secondary mutations restore replicative fitness to HBV \[[@B5]\]. The primary resistance mutations are rtM204V/I within the YMDD motif for lamivudine, rtN236T, and/or rtA181T/V for adefovir. Telbivudine has a high degree of cross-resistance with lamivudine, with its primary resistance mutation M204I and secondary mutations L80I/V or L180M \[[@B6]\]. Entecavir has two distinct patterns of resistance that both include the YMDD mutation associated with lamivudine resistance, rtI169T + rtL180M + rtM204V + rtM250V and rtL180M + rtT184G + rtS202I + rtM204V; however, other resistance patterns have been reported \[[@B5]\].

HBV replication includes an inherently error prone reverse transcriptase, as it does not have a 3′-5′ proofreading exonuclease activity. On average approximately 10^11^ virions are produced daily \[[@B7]\], with estimated 8 × 10^−5^ mutations/base pair/year \[[@B8]\]. Exposure to oral antiviral agents selects naturally occurring mutations with intrinsic antiviral resistance. Generally these less replicatively fit than "wild type" HBV and therefore do not persist in circulating blood in the absence of an agent inducing resistance. Although drug resistant mutants are selected by antiviral therapy, a number of reports have described their identification in apparently treatment naïve subjects with lamivudine resistance mutations, specifically the M204I/V ranging from 0.8 to 27% \[[@B9], [@B10], [@B11], [@B12], [@B13], [@B14], [@B15], [@B16], [@B17]\]. Implications of HBV resistance mutants in treatment naïve patients include concerns about the inappropriate use of agents with similar resistance patterns. Furthermore transmission of HBV resistant mutants to others has been recognized. Generally reports of detection of antiviral resistant mutants in treatment naïve patients have been in sera collected after the introduction of the oral antiviral agents; further, several reports do not specify the timeframe from which sera was collected hence making interpretation of this relationship more difficult. The aim of our study was to determine whether resistant mutations were present before the era of antiviral HBV therapy.

2. Methods and Materials {#sec2}
========================

We used deidentified residual blood sera collected from July 1986 to July 1992 at the University of Miami. Blood samples were centrifuged, aliquoted, and then stored at −20°C until testing. The study was approved by the University of Miami Institutional Review Board. All of the patients had chronic HBV infection (detectable HBsAg positive for at least 6 months) with a detectable viral load (at least 10 pg/mL), HBeAg seropositivity, and absence of HIV coinfection (negative anti-HIV by enzyme immunoassay). All sera were obtained from patients naïve to oral antiviral therapy. Serological markers of HBV were analyzed using commercially available enzyme immunoassay kits (Abbott Laboratories, Abbott Park, IL and Roche). HBV DNA assay was performed with the Abbott Liquid Hybridization HBV DNA quantitative assay (Genostics, Abbott, Chicago, IL). Genotyping was done with the INNO-LiPA HBV genotype kit (Innogenetics, Belgium). Amplification of HBV DNA was completed with the Roche high pure viral nucleic acid kit (Roche Diagnostics, Indianapolis, IN) and the mutation analysis was accomplished with the INNO-LiPA HBV DR v2/v3 (Innogenetics, Belgium). The INNO-LiPA HBV DR v2/3 reverse hybridization assay can detect single nucleotide mismatches associated with lamivudine, adefovir, and entecavir resistance comprising 5% or more of the viral population \[[@B5]\]. Descriptive statistics were processed using the SAS 9.2 program package (SAS Institute, Inc., Cary, NC).

3. Results {#sec3}
==========

Of the 50 patients whose sera were included 86% were male, average age was 40 ± 12 years, 86% were genotype A, 6% were genotype F, 3.5% were genotype D, and 3.5% were genotype C with a mean HBV DNA of 126 pg/mL ([Table 1](#tab1){ref-type="table"}). No detectable mutations were present in 47 of the 50 samples with INNO-LiPA HBV DR 2/3 testing. Three of the 50 samples had indeterminate results for certain codons (180/181, 236, and 250); these three samples were submitted to InnoGenetics Laboratories in Belgium where direct PCR sequencing confirmed that there were no mutations within these codons.

4. Discussion {#sec4}
=============

Our results suggest that prior to the introduction of oral antiviral agents HBV resistant mutants were absent in treatment naïve patients. Detection of HBV resistant mutants in treatment naïve patients in other reports has a number of possible explanations. Patients may have contracted HBV by contact with a treatment experienced patient. Alternatively patients may have had unrecognized exposure to antiviral agents, for instance, contained in herbal preparations. A number of other groups have reported the presence of resistant HBV mutants in treatment naïve patients. To determine whether these reports were pertinent the following criteria were applied: (1) treatment naïve hepatitis B treatment, (2) absence of HIV coinfection, (3) hepatitis B DNA polymerase mutation testing performed (any method), (4) the time period of blood sera collection specified, and (5) including 10 or more subjects. We identified 18 reports, including abstracts, for further analysis ([Table 2](#tab2){ref-type="table"}). Only one of the eighteen papers examined sera in the before 1995 era, Matsuda et al. \[[@B9]\]. An additional paper performed a phylogenetic cluster analysis on HBV sequences before 1995 from the National Center Biotechnology Institute database \[[@B12]\].

Matsuda et al. evaluated 50 Japanese patients\' sera, the majority obtained pre-1995. Twenty (40%) were asymptomatic carriers, and sera were assessed by PCR (both by enzyme-linked minisequence assay and by restriction fragment length polymorphism). Sera were collected from 1979 to 1989 and the YMDD motif was specifically sought. No mutations were noted. A second group of 10 (20%) individuals had their sera examined prior to lamivudine therapy and were assessed for surface antigen loss. All screening sera were collected from 1976 to 1992 and sequenced by PCR for YMDD mutation and found to be negative. Lastly, there was a third group of 20 individuals who were treated with lamivudine; however, prior to initiating lamivudine therapy, the YMDD motif was assessed among treatment subjects, and sera had been collected from 1994 to 2000. No treatment induced mutations were detected in this group \[[@B9]\].

In another report Chinese investigators sought to determine if widespread oral antiviral use had increased resistance to therapy and whether drug resistant strains had been transmitted by patients \[[@B12]\]. Direct PCR sequencing was performed from 328 treatment naïve patients, predominantly genotype C and HBeAg positive. Approximately 4% of patients had lamivudine associated viral resistance mutations, less than 1% had adefovir (0.6%), and entecavir (0.3%) related viral mutants. Phylogenetics were performed to assess the genetic distance between HBV reverse transcriptase sequences in sera collected between 2005 and 2006 and controls submitted to the National Center for Biotechnology Information (GenBank) before 1995. Phylogenetic analysis is a method used to assess genetic evolutionary changes over a period of time. The cohort compared to the genetic bank was found to be similar (genetic distance of 0.02), allowing the authors to conclude that the advent of nucleos(t)ide therapy did not accelerate evolutionary change \[[@B12]\].

Kobayashi et al. \[[@B10]\] reported the presence of viral mutants in eighteen treatment naïve chronic HBV patients. 13 (72%) of whom had the YMDD wild type, while 5 (28%) had mutants. Samples had been collected between 1997 and 1999 from treatment naïve patients. Other reports, with the exception of Matsuda et al. \[[@B9]\], ([Table 2](#tab2){ref-type="table"}) had samples from 1995 onwards, all with variable results and frequencies of viral mutants.

There are some limitations to our study. First, the sample size is relatively small. From our literature search, of the eighteen selected papers ([Table 2](#tab2){ref-type="table"}), 75% had sample sizes larger than 50, with the average size including approximately 170 patients. Second, we had three of the fifty samples that had indeterminate results on the INNO-LiPA DR2/3 testing. These samples were confirmed to not have resistance mutations; however, at the expense of a relatively less sensitive test, direct PCR sequencing. Third, reverse hybridization assay, such as INNO-LiPA is known to be extremely sensitive (able to detect viral resistance constituting 5% or more of the total viral population); however, the test does not detect novel mutations and may not be as sensitive as ultradeep pyrosequencing (UDPS) \[[@B11], [@B27]\]. Finally as the samples were deidentified limited demographic information could be obtained about the subjects, such as ethnicity. In regard to ethnicity, however, as the majority of subjects had genotype A, one could infer that they were of North American-European descent.

In conclusion, our results support the hypothesis that HBV drug resistance mutations did not antedate introduction of oral antiviral agents and that the detection of drug resistance in an apparently treatment naïve subject suggests either unrecognized prior antiviral therapy or infection by an inoculum from a treatment experienced patient.
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###### 

Clinical and laboratory characteristics of the study population.

  Characteristic                     Values
  ---------------------------------- --------------------
  Patients *N*                       50
   Male *N* (%)                      43 (86)
   Female *N* (%)                    7 (14)
  Years of age, mean ± SD (range)    40 ± 12 (19--65)
  HBV DNA, mean pg/mL ± SD (range)   126 ± 121 (6--557)
  HBV genotype *N* (%)                
   A                                 43 (86)
   B                                 0
   C                                 2 (3.5)
   D                                 2 (3.5)
   E                                 0
   F                                 3 (6)

###### 

Presence of DNA polymerase mutations in chronic monoinfected hepatitis B treatment naïve.

  Author, year                                Country         Time frame   *N*   Method(s)   Presence of DR mutations   Presence of LAM DR mutations
  ------------------------------------------- --------------- ------------ ----- ----------- -------------------------- ------------------------------
  Matsuda et al. 2004 \[[@B9]\]               Japan           1976--2000   50    PCR         N                          N
  Matsuda et al. 2004 \[[@B18]\]              Japan           1995--2001   71    PCR         Y                          Y
  Kobayashi et al. 2001 \[[@B10]\]            Japan           1997--1999   18    PCR         Y                          Y
  Margeridon-Thermet et al. 2009 \[[@B11]\]   United States   1998--2007   17    PCR/UDPS    Y                          Y
  Amini-Bavil-Olyaee et al. 2008 \[[@B19]\]   Iran            2002--2006   147   PCR         N                          N
  Pollicino et al. 2009 \[[@B20]\]            Italy           2002--2007   100   PCR         N                          N
  Han et al. 2009 \[[@B12]\]                  China           2005-2006    328   PCR         Y                          Y
  Nguyen et al. 2009 \[[@B21]\]               United States   2005--2008   472   PCR         Y                          Y
  Fung et al. 2008 \[[@B13]\]                 Canada          2006--2008   209   RHA         Y                          Y
  Liu et al. 2010 \[[@B22]\]                  China           2007-2008    192   PCR         N                          N
  Mirandola et al. 2011 \[[@B14]\]            Italy           2007--2009   255   RHA         Y                          Y
  Fung et al. 2009 \[[@B15]\]                 Canada          2007--2009   311   RHA         Y                          Y
  Salpini et al. 2011 \[[@B23]\]              Europe          2007--2010   140   PCR         Y                          N
  Sayan et al. 2010 \[[@B24]\]                Turkey          2008-2009    88    PCR         Y                          N
  Osiowy et al. 2011 \[[@B16]\]               Canada          2008-2009    201   RHA/UDPS    Y                          Y
  Ng et al. 2009 \[[@B17]\]                   Canada          2008-2009    175   RHA         Y                          Y
  Nguyen et al. 2009 \[[@B25]\]               United States   2009         70    RHA         N                          N
  Nguyen et al. 2011 \[[@B26]\]               United States   2009--2011   200   RHA         Y                          N

Key: time frame: time range of blood sera collection; *N*: number of naïve treated subjects; method(s): method(s) used to detect genotypic resistance mutations; DR: drug resistance; LAM: lamivudine; PCR: polymerase chain reaction; UDPS: ultradeep pyrosequencing; RHA: reverse hybridization assay; Y: yes; N: no.
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